VALNEVA SE (VLA.PA)

FR0004056851 - Common Stock

1.924  -0.08 (-3.99%)

Fundamental Rating

3

Overall VLA gets a fundamental rating of 3 out of 10. We evaluated VLA against 75 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VLA has reported negative net income.
In the past year VLA has reported a negative cash flow from operations.
VLA had negative earnings in each of the past 5 years.
In multiple years VLA reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.66%, VLA is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
With a decent Return On Equity value of -4.64%, VLA is doing good in the industry, outperforming 71.43% of the companies in the same industry.
Industry RankSector Rank
ROA -1.66%
ROE -4.64%
ROIC N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of VLA (38.72%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of VLA has declined.
VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%

More info and screens

3

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VLA has more shares outstanding
VLA has more shares outstanding than it did 5 years ago.
VLA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.44, we must say that VLA is in the distress zone and has some risk of bankruptcy.
VLA has a Altman-Z score (-0.44) which is in line with its industry peers.
VLA has a Debt/Equity ratio of 1.13. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.13, VLA is not doing good in the industry: 67.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.13
Debt/FCF N/A
Altman-Z -0.44
ROIC/WACCN/A
WACC7.71%

2.3 Liquidity

A Current Ratio of 2.63 indicates that VLA has no problem at all paying its short term obligations.
VLA has a Current ratio (2.63) which is comparable to the rest of the industry.
VLA has a Quick Ratio of 2.15. This indicates that VLA is financially healthy and has no problem in meeting its short term obligations.
VLA has a Quick ratio (2.15) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.15

More info and screens

5

3. Growth

3.1 Past

VLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.90%, which is quite impressive.
The Revenue for VLA has decreased by -44.52% in the past year. This is quite bad
Measured over the past years, VLA shows a small growth in Revenue. The Revenue has been growing by 6.34% on average per year.
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%

3.2 Future

VLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.05% yearly.
VLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.69% yearly.
EPS Next Y97.18%
EPS Next 2Y21.89%
EPS Next 3Y21.58%
EPS Next 5Y36.05%
Revenue Next Year10.18%
Revenue Next 2Y13.08%
Revenue Next 3Y18.76%
Revenue Next 5Y22.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VLA's earnings are expected to grow with 21.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.89%
EPS Next 3Y21.58%

More info and screens

0

5. Dividend

5.1 Amount

VLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

EPA:VLA (12/20/2024, 7:00:00 PM)

1.924

-0.08 (-3.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-18 2025-02-18/amc
Inst Owners25.93%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap156.23M
Analysts83.08
Price Target7.76 (303.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.36%
Min EPS beat(2)-44.01%
Max EPS beat(2)72.74%
EPS beat(4)1
Avg EPS beat(4)-7.87%
Min EPS beat(4)-44.01%
Max EPS beat(4)72.74%
EPS beat(8)3
Avg EPS beat(8)-42.29%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.98%
Min Revenue beat(2)-14.39%
Max Revenue beat(2)-13.58%
Revenue beat(4)1
Avg Revenue beat(4)-7.48%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)3.98%
Revenue beat(8)4
Avg Revenue beat(8)24.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.1%
PT rev (3m)-16.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-216.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 1.1
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.51
OCFYN/A
SpS2.73
BVpS2.05
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.66%
ROE -4.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.72%
FCFM N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
F-Score1
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.11%
Cap/Sales 5.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.15
Altman-Z -0.44
F-Score1
WACC7.71%
ROIC/WACCN/A
Cap/Depr(3y)291.07%
Cap/Depr(5y)239.89%
Cap/Sales(3y)14.73%
Cap/Sales(5y)14.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
EPS Next Y97.18%
EPS Next 2Y21.89%
EPS Next 3Y21.58%
EPS Next 5Y36.05%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%
Revenue Next Year10.18%
Revenue Next 2Y13.08%
Revenue Next 3Y18.76%
Revenue Next 5Y22.69%
EBIT growth 1Y-157.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year160.39%
EBIT Next 3Y30.6%
EBIT Next 5Y25.83%
FCF growth 1Y-21.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.33%
OCF growth 3YN/A
OCF growth 5YN/A